Similar articles for PMID: 21102269

Year	Number of Results
1989	1
2008	1
2009	2
2010	5
2011	7
2012	12
2013	16
2014	23
2015	23
2016	8
2017	13
2018	6
2019	3
2020	1
2021	1
2022	2
2024	0

1

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Ou SH, et al. J Thorac Oncol. 2010 Dec;5(12):2044-6. doi: 10.1097/JTO.0b013e318200f9ff. J Thorac Oncol. 2010. PMID: 21102269 Free article. No abstract available.

2

ALK, lung cancer, and personalized therapy: portent of the future?

Garber K. Garber K. J Natl Cancer Inst. 2010 May 19;102(10):672-5. doi: 10.1093/jnci/djq184. Epub 2010 May 11. J Natl Cancer Inst. 2010. PMID: 20460631 No abstract available.

3

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Loong HH, Mok K, Leung LK, Mok TS. Loong HH, et al. Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314. Future Oncol. 2015. PMID: 25757678 Review.

4

ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.

Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD. Yamamoto S, et al. Radiology. 2014 Aug;272(2):568-76. doi: 10.1148/radiol.14140789. Epub 2014 Jun 2. Radiology. 2014. PMID: 24885982 Clinical Trial.

5

High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.

Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC. Feng Y, et al. J Thorac Oncol. 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145. J Thorac Oncol. 2014. PMID: 24722154 Free article.

6

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Lu S, Azada MC, Ou SH. Lu S, et al. Lung Cancer. 2015 Feb;87(2):207-9. doi: 10.1016/j.lungcan.2014.12.011. Epub 2014 Dec 19. Lung Cancer. 2015. PMID: 25558789

7

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI. Rodig SJ, et al. Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Curr Opin Investig Drugs. 2010. PMID: 21154129 Review.

8

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O. Mazières J, et al. J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9. J Clin Oncol. 2015. PMID: 25667280

9

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K. Sun JM, et al. J Thorac Oncol. 2012 Dec;7(12):e36-e38. doi: 10.1097/JTO.0b013e318274694e. J Thorac Oncol. 2012. PMID: 23154564 Free article. No abstract available.

10

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

Kaneda H, Okamoto I, Nakagawa K. Kaneda H, et al. J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771. J Thorac Oncol. 2013. PMID: 23486271 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

112 results

Results by year